The COMBAT project uses AI, advanced genomics, and organ-on-chip technology to understand why dengue becomes severe in some patients, with India leading genomics research. Two dengue vaccines are advancing: Takeda's Qdenga received Indian regulatory approval with 84.1% efficacy, while ICMR's DengiAll is in Phase III trials across 20 sites.
The Indian Express
· Apr 29, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Global science race accelerates to crack dengue's deadly code
Dengue incidence has increased dramatically from 505,000 cases in 2000 to 14.6 million in 2024, with projections suggesting further 60% increase by mid-century.
◉
Health & Medicine
8098 artículos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% coincidencia
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% coincidencia
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% coincidencia
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% coincidencia
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% coincidencia
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Sesgo y Encuadre
⚖
Article presents international dengue research efforts with positive framing of India's scientific contributions, using optimistic language about technological advances without significant critical perspective.
Bias Direction
center-left
Confidence
MED
Progress narrative emphasizing scientific advancement and international collaboration, with India positioned as a capable research partner. Uses aspirational language ('leap forward,' 'accelerates') to frame research efforts positively.
deadly code
crack dengue's deadly code
accelerates
leap forward
surged
growing risk
Cost-effectiveness and accessibility of new technologies for developing nations
Challenges in implementing findings in resource-limited settings
Ethical concerns regarding organ-on-chip and AI research applications
Voices of dengue patients or affected communities
Criticism or skepticism about timeline feasibility
Perspectives from competing research programs or alternative approaches
Public health infrastructure gaps that may hinder implementation
Impacto Geopolítico
🌎
International dengue research initiative led by EU and India accelerates vaccine development and genomics research, positioning India as a key biotech hub while addressing a rapidly expanding global health threat.
Escalation Risk
low
Confidence
HIGH
India
European Union
Sweden
Southeast Asia
Global (endemic and non-endemic regions)
India strengthens its position as a biomedical research powerhouse through EU collaboration, gaining access to advanced technologies and funding while establishing itself as essential to global health security. EU leverages Indian genomics expertise and clinical infrastructure. This represents a shift toward multipolar health governance with emerging economies as equal research partners rather than passive recipients.
Similar to the polio eradication initiative (1988-present) where international collaboration combined developed-nation funding with developing-nation field expertise and population access, creating sustainable global health infrastructure.
Lente Económico
📈
International dengue research initiatives with India's significant genomics contribution are accelerating vaccine development and public health infrastructure, addressing a disease surge from 505K to 14.6M cases globally.
Market Signal
bullish
Confidence
HIGH
Biotechnology and pharmaceutical manufacturing
Healthcare and medical devices
Public health infrastructure
Research and development
Medical tourism and diagnostics
Consumers benefit from accelerated vaccine development reducing dengue infection risks, improved diagnostic capabilities, and strengthened public health surveillance. Healthcare costs may decrease long-term through prevention, though short-term vaccine pricing and healthcare spending may increase.
Governments likely to increase biotech R&D funding, strengthen disease surveillance infrastructure, expedite vaccine approval processes, and potentially mandate dengue vaccination in endemic regions. International collaboration frameworks may expand for pandemic preparedness. India's biotech sector may receive policy support for technology transfer and manufacturing capacity.